logo-loader
viewHumanigen, Inc.

Humanigen wins hematological society award for leukemia treatment presentation

The company won an Abstract Achievement Award for one of its two presentations at the American Society of Hematology's annual meeting

Trophy
The drug, a monoclonal antibody, works to improve CAR-T, a new approach to cancer therapy involving altered T cells

Humanigen Inc (OTCMKTS:HGEN) received an award from the American Society of Hematology (ASH) after presenting an abstract at the organization's annual meeting last week.

The company won a 2019 ASH Abstract Achievement Award for one of its two presentations, which showed results from a study of its drug candidate lenzilumab.

The drug, a monoclonal antibody, works to improve CAR-T, a new approach to cancer therapy involving altered T cells. Humanigen said a xenograft model for relapsed acute lymphoblastic leukemia showed improved overall survival compared to another treatment called CART19.

READ: Humanigen to present abstracts highlighting its glioblastoma treatments at industry conference

Specifically, it works to neutralize the protein GM-CSF using activated CAR-T cells, a modified form of the white blood cell subset.

"It is gratifying to receive recognition for the second year in succession that we have presented GM-CSF -related data for the pioneering work that we are conducting to make CAR-T therapy potentially more efficacious and safer through GM-CSF neutralization," CEO Cameron Durrant said in a statement. "We are looking forward to bringing lenzilumab into the clinic as we begin dosing patients in ZUMA-19 in 2020 with our partner, Kite Pharma."

The Burlingame, California-based company plans to work with Kite to study lenzilumab as a potential treatment for patients with relapsed diffuse large B-cell lymphoma. 

Kite, owned by Gilead Sciences Inc (NASDAQ:GILD), has developed the drug Yescarta, which lenzilumab will be paired with, in the study.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: 0.38 USD

OTCQB:HGEN
Market: OTCQB
Market Cap: $42.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen updates on its clinical collaboration with Gilead Sciences...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco.  Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with...

on 10/23/2019

2 min read